KRAS mutations(m) in lung adenocarcinoma (AC) patients(p) receiving standard chemotherapy (ch) and immune checkpoint inhibitors (i-CI): Impact of KRAS clonality and coexisting TP53m
Aranda, N. Pardo, Ruiz, F., Marti, A. Martinez, Cedres, S., Mendivil, A. Navarro, fuente, I. de la, de Castro, A. Martinez, Vivancos, A., Dienstmann, R., Felip, E.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw383.71
Date:
October, 2016
File:
PDF, 64 KB
english, 2016